symptoms commonly occurring in schizophrenia, it could be hypothesized that the CCK-A receptor gene may be associated with the positive symptoms of schizophrenia. In a recent study conducted with a large sample size, we also found that the CCK-A receptor gene was significantly associated with the HDS in a Caucasian population (unpublished data). The A1 frequency was 0.176 in schizophrenic patients with the HDS and 0.087 in those without the HDS ( Interaction of two genes possibly involved in the regulation of the amyloid precursor protein (APP) processing SIR -An intronic polymorphism of the gene encoding the transmembrane protein presenilin 1 (PS1) was found to be associated with increased risk for sporadic AD (ie over-representation of allele 1 in AD), 1 however, this observation has been challenged by subsequent studies. These inconsistent findings might result from interactions of PS1 with other susceptibility genes and their products. Recently, Xia et al 2 identified PS1 to be crucial for the catalytic activity of the ␥-secretase, which is one of the two yet unidentified proteases (␤-and ␥-secretase) responsible for cleavage of the amyloid precursor protein (APP) into amyloidogenic components (␤A4).
Cathepsin D (catD), an acid protease active in intracellular protein breakdown, has in vitro ␤-and ␥-secretase-like properties and has also been implicated in the pathogenesis of AD. An exonic polymorphism of the catD gene (allele T) was recently found to be a major risk factor for the development of sporadic AD. 3 Wolfe et al 4 proposed that ␥-secretase is an aspartyl protease with properties similar to those of cathepsin D. Thus, both genetic and biochemical data suggest an involvement of PS1 and catD in the cleavage and further processing of APP. Given this evidence, we hypothesised that genetic interactions between PS1 and catD would modify the risk for the development of sporadic AD and might be responsible for the conflicting reports on the association of the PS1 genotype with AD.
We investigated a sample of 217 patients with sporadic AD (mean age 72.6 ± 9.7 years, 62.2% female) and of 434 non-demented control subjects (mean age 68.2 ± 10.6 years, 56.0% female) recruited at two centres and 243 controls). Gene interactions were tested by forward and backward logistic regression analysis.
The results (Table 1) show that, while allele 1 of the PS1 gene was not associated with increased risk for AD in the entire sample (odds ratio = 1.2; 95% CI: 0.8-1.8), there was a considerable difference in the distribution of the PS1 genotype when the population was stratified according to the catD genotype: Allele 1 of the PS1 gene doubled the AD risk in persons with at least one T allele of the catD gene (odds ratio = 2.54; 95% CI: 1.01-6.43), whereas it had no influence on AD risk in persons lacking the T allele (odds ratio = 1.00; 95% CI: 0.62-1.62). Logistic regression confirmed this observation. Besides age (P Ͻ 0.001) and the apolipoprotein E*4 allele (P Ͻ 0.001), the interaction of the PS1 and catD polymorphisms significantly modified the AD risk (odds ratio = 2.5; P = 0.004). Separate examination of the test hypothesis by recruitment site (Bonn/Munich) yielded consistent results between centres.
The present study shows that interaction of the genes Molecular Psychiatry coding for PS1 and catD significantly modifies the risk for the development of sporadic AD. Allele 1 of the PS1 gene increased the AD risk only in subjects carrying at least one T allele of the catD gene, which is also a risk factor for AD. This genetic interaction might have pathophysiological consequences. The catD*T allele has been associated with altered intracellular maturation of catD, 5 which is an enzyme with in vitro ␤-and ␥-secretase-like properties. 4, 6 Assuming PS1 is crucial for a proper ␥-secretase activity and allele 1 of the PS1 genotype is associated with increased AD risk, the interaction of these two genes should influence APP processing and therefore modify the risk for AD. The present study provides an explanation for the conflicting reports on the association of the PS1 genotype with AD.
